Questcor Pharmaceuticals, Inc.
http://www.questcor.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Questcor Pharmaceuticals, Inc.
US FDA 2020 Novel Approval Count Rises To 53 At CDER, Plus 5 New CBER Biologics
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.
Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Revance Builds Therapeutics Credibility For DaxibotulinumtoxinA Ahead Of Aesthetics Launch
The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.
Company Information
- Other Names / Subsidiaries
-
- BioVectra Inc.